The role of human nucleoside transporters in cellular uptake of 4′-Thio-β-D-arabinofuranosylcytosine and β-D-arabinosylcytosine

Molecular Pharmacology

Volumn 70, Issue 1, 2006, Pages 303-310

  Clarke, Marilyn L ^a,c   Damaraju, Vijaya L ^a   Zhang, Jing ^a   Mowles, Delores ^a   Tackaberry, Tracey ^a   Lang, Thach ^a   Smith, Kyla M ^a   Young, James D ^a   Tomkinson, Blake ^b   Cass, Carol E ^a,d  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Global Health Outcomes and Market Access   (United States)

^c GTI Inc   (United States)

^d CROSS CANCER INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4' THIO BETA DEXTRO ARABINOSYLCYTOSINE; CYTARABINE; CYTOSINE; DEOXYCYTIDINE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 2; NITROBENZYLTHIOINOSINE; UNCLASSIFIED DRUG; URIDINE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CHEMOSENSITIVITY; CYTOTOXICITY; DRUG ACTIVITY; DRUG BINDING; DRUG EXPOSURE; DRUG UPTAKE; ELECTROPHYSIOLOGY; HUMAN; HUMAN CELL; NONHUMAN; OOCYTE; PRIORITY JOURNAL; PROTEIN FUNCTION; WILD TYPE; XENOPUS LAEVIS;

ANIMALS; ARABINONUCLEOSIDES; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CELL SURVIVAL; CYTARABINE; CYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EQUILIBRATIVE-NUCLEOSIDE TRANSPORTER 2; FEMALE; HELA CELLS; HUMANS; MEMBRANE POTENTIALS; NUCLEOSIDE TRANSPORT PROTEINS; OOCYTES; SACCHAROMYCES CEREVISIAE; THIOINOSINE; TRANSFECTION; TRITIUM; URIDINE; XENOPUS LAEVIS;

EID: 33745261801     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.105.021543     Document Type: Article

References (41)

1. Baldwin SA, Yao SY, Hyde RJ, Ng AM, Foppolo S, Barnes K, Ritzel MW, Cass CE, and Young JD (2005) Functional characterisation of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. J Biol Chem 280:15880-15887.
2. 2 arrest. Proc Am Assoc Cancer Res 43:abstract 4779.
3. Boleti H, Coe IR, Baldwin SA, Young JD and Cass CE (1997) Molecular identification of the equilibrative NBMPR-sensitive (es) nucleoside transporter and demonstration of an equilibrative NBMPR-insensitive (ei) transport activity in human erythroleukemia (K562) cells. Neuropharmacology 36:1167-1179.
4. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
5. Clarke ML, Mowles D, Vickers MF, Zhang J, Young JD, Tomkinson B, and Cass CE (2003) Uptake of 4′-thio-β-D-arabinofuranosylcytosine and β-D-arabinosylcytosine by human equilibrative and concentrative nucleoside transporters. Proc Am Assoc Cancer Res 44:abstract 3699.
6. Damaraju VL, Visser F, Zhang J, Mowles D, Ng AM, Young JD, Jayaram HN, and Cass CE (2005) Role of human nucleoside transporters in the cellular uptake of two inhibitors of IMP dehydrogenase, tiazofurin and benzamide riboside. Mol Pharmacol 67:273-279.
7. Gati WP, Paterson AR, Larratt LM, Turner AR, and Belch AR (1997) Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein. Blood 90:346-353.
8. Gelbard AS, Kim JH, and Perez AG (1969) Fluctuations in deoxycytidine monophosphate deaminase activity during the cell cycle in synchronous populations of HeLa cells. Biochim Biophys Acta 182:564-566.
9. Gourdeau H, Bibeau L, Ouellet F, Custeau D, Bernier L, and Bowlin T (2001a) Comparative study of a novel nucleoside analogue (troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity. Cancer Chemother Pharmacol 47:236-240.
10. Gourdeau H, Clarke ML, Ouellet F, Mowles D, Selner M, Richard A, Lee N, Mackey JR, Young JD, Jolivet J, et al. (2001b) Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines. Cancer Res 61:7217-7224.
11. Graham KA, Leithoff J, Coe IR, Mowles D, Mackey JR, Young JD, and Cass CE (2000) Differential transport of cytosine-containing nucleosides by recombinant human concentrative nucleoside transporter protein hCNT1. Nucleosides Nucleotides Nucleic Acids 19:415-434.
12. Griffiths M, Beaumont N, Yao SY, Sundaram M, Boumah CE, Davies A, Kwong FY, Coe I, Cass CE, Young JD, et al. (1997a) Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs. Nat Med 3:89-93.
13. Griffiths M, Yao SY, Abidi F, Phillips SE, Cass CE, Young JD, and Baldwin SA (1997b) Molecular cloning and characterization of a nitrobenzylthioinosine- insensitive (ei) equilibrative nucleoside transporter from human placenta. Biochem J 328:739-743.
14. Jamieson GP, Snook MB, and Wiley JS (1990) Saturation of intracellular cytosine arabinoside triphosphate accumulation in human leukemic blast cells. Leuk Res 14:475-479.
15. Lang TT, Selner M, Young JD, and Cass CE (2001) Acquisition of human concentrative nucleoside transporter 2 (hcnt2) activity by gene transfer confers sensitivity to fluoropyrimidine nucleosides in drug-resistant leukemia cells. Mol Pharmacol 60:1143-1152.
16. Lang TT, Young JD, and Cass CE (2004) Interactions of nucleoside analogs, caffeine and nicotine with human concentrative nucleoside transporters 1 and 2 stably produced in a transport-defective human cell line. Mol Pharmacol 65:925-933.
17. Mackey JR, Baldwin SA, Young JD, and Cass CE (1998a) Nucleoside transport and its significance for anticancer drug resistance. Drug Resist Updat 1:310-324.
18. Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, Crawford CR, and Cass CE (1998b) Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 58:4349-4357.
19. Meyers R, Malathi VG, Cox RP, and Silber R (1973) Studies on nucleoside deaminase. Increase in activity in HeLa cell cultures caused by cytosine arabinoside. J Biol Chem 248:5909-5913.
20. Parker WB, Shaddix SC, Rose LM, Waud WR, Shewach DS, Tiwari KN, and Secrist JA (2000) Metabolism of 4′-thio-beta-D-arabinofuranosylcytosine in CEM cells. Biochem Pharmacol 60:1925-1932.
21. Richardson F, Black C, Richardson K, Franks A, Wells E, Karimi S, Sennello G, Hart K, Meyer D, Emerson D, et al. (2005) Incorporation of OSI-7836 into DNA of Calu-6 and H460 xenograft tumors. Cancer Chemother Pharmacol 55:213-221.
22. Richardson KA, Vega TP, Richardson FC, Moore CL, Rohloff JC, Tomkinson B, Bendele RA, and Kuchta RD (2004) Polymerization of the triphosphates of AraC, 2′,2′-difluorodeoxycytidine (dFdC) and OSI-7836 (T-araC) by human DNA polymerase alpha and DNA primase. Biochem Pharmacol 68:2337-2346.
23. Ritzel MW, Yao SY, Ng AM, Mackey JR, Cass CE, and Young JD (1998) Molecular cloning, functional expression and chromosomal localization of a cDNA encoding a human Na+/nucleoside cotransporter (hCNT2) selective for purine nucleosides and uridine. Mol Membr Biol 15:203-211.
24. +- nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). J Biol Chem 276:2914-2927.
25. +-nucleoside cotransporter (hCNT1). Am J Physiol 272:C707-C714.
26. +-coupled nucleoside transporter (hCNT1) produced in Xenopus oocytes. J Physiol (Lond) 558:807-823.
27. +/nucleoside cotransporter (hCNT3) exhibits novel cation-coupled nucleoside transport characteristics. J Biol Chem 280:25436-24439.
28. Someya H, Shaddix SC, Tiwari KN, Secrist JA 3rd, and Parker WB (2003) Phosphorylation of 4′-thio-β-D-arabinofuranosylcytosine and its analogs by human deoxycytidine kinase. J Pharmacol Exp Ther 304:1314-1322.
29. Someya H, Tiwari KN, Secrist JA, and Parker WB (2002) Structure-activity relationship of 4′-thionucleoside analogs with deoxycytidine kinase (dCK) from CEM cells. Proc Am Assoc Cancer Res 43:abstract 3674.
30. Someya H, Waud WR, and Parker WB (2005) Long intracellular retention of 4′-thio-arabinofuranosylcytosine 5′-triphosphate as a critical factor for the anti-solid tumor activity of 4′-thio- arabinofuranosylcytosine. Cancer Chemother Pharmacol 57:772-780.
31. Thottassery JV, Westbrook L, Someya H, and Parker WB (2006) c-Abl-independent p73 stabilization during gemcitabine- or 4′-thio-{beta}- D-arabinofuranosylcytosine-induced apoptosis in wild-type and p53-null colorectal cancer cells. Mol Cancer Ther 5:400-410.
32. Ullman B (1989) Dideoxycytidine metabolism in wild type and mutant CEM cells deficient in nucleoside transport or deoxycytidine kinase. Adv Exp Med Biol 253B:415-420.
33. Ullman B, Coons T, Rockwell S, and McCartan K (1988) Genetic analysis of 2′,3′-dideoxycytidine incorporation into cultured human T lymphoblasts. J Biol Chem 263:12391-12396.
34. Vickers MF, Kumar R, Visser F, Zhang J, Charania J, Raborn RT, Baldwin SA, Young JD, and Cass CE (2002) Comparison of the interaction of uridine, cytidine and other pyrimidine nucleoside analogues with recombinant human equilibrative nucleoside transporter 2 (hENT2) produced in Saccharomyces cerevisiae. Biochem Cell Biol 80:639-644.
35. Vickers MF, Zhang J, Visser F, Tackaberry T, Robins MJ, Nielsen LP, Nowak I, Baldwin SA, Young JD, and Cass CE (2004) Uridine recognition motifs of human equilibrative nucleoside transporters 1 and 2 produced in Saccharomyces cerevisiae. Nucleosides Nucleotides Nucleic Acids 23:361-373.
36. Visser F, Vickers MF, Ng AM, Baldwin SA, Young JD, and Cass CE (2002) Mutation of residue 33 of human equilibrative nucleoside transporters 1 and 2 alters sensitivity to inhibition of transport by dilazep and dipyridamole. J Biol Chem 277:395-401.
37. Waud WR, Gilbert KS, Shepherd RV, Montgomery JA, and Secrist JA 3rd (2003) Preclinical antitumor activity of 4′-thio-beta-D- arabinofuranosylcytosine (4′-thio-ara-C). Cancer Chemother Pharmacol 51:422-426.
38. Whistler RL, Doner LW, and Nayak UG (1971) 4-Thio-D- arabinofuranosylpyrimidine nucleosides. J Org Chem 36:108-110.
39. Wiley JS, Taupin J, Jamieson GP, Snook M, Sawyer WH, and Finch LR (1985) Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma. J Clin Investig 75:632-642.
40. Zhang J, Smith KM, Tackaberry T, Visser F, Robins MJ, Nielsen LP, Nowak I, Karpinski E, Baldwin SA, Young JD, et al. (2005) Uridine binding and transportability determinants of human concentrative nucleoside transporters. Mol Pharmacol 68:830-839.
41. Zhang J, Visser F, Vickers MF, Lang T, Robins MJ, Nielsen LP, Nowak I, Baldwin SA, Young JD, and Cass CE (2003) Uridine binding motifs of human concentrative nucleoside transporters 1 and 3 produced in Saccharomyces cerevisiae. Mol Pharmacol 64:1512-1520.